In Vitro Cytotoxicity of Bismuth-213 (213bi)-Labeled-Plasminogen Activator Inhibitor Type 2 (Alpha-PAI-2) on Human Breast Cancer Cells

Biological and clinical aspects of plasminogen activator inhibitor type 2

EK Kruithof, Mark S. Baker, C. L. Bunn · Blood · 1995 · 340 citations · Full text

Life Sciences, Pharmacotherapy, Clinical Pharmacology +6

An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.

Michael R. McDevitt, E Barendswaard, Dangshe Ma et al. · PubMed · 2000 · 258 citations

Medicine, Nuclear Medicine, Oncology +17

Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.

Tuomo Nikula, Michael R. McDevitt, Ronald D. Finn et al. · PubMed · 1999 · 177 citations

Medicine, Nuclear Medicine, Pharmacokinetics +17

The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue.

Elisabetta Bianchi, Roger Cohen, Ann Thor et al. · PubMed · 1994 · 151 citations

Medicine, Oncology, Pathology +17

An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation

Michael R. McDevitt, Ronald D. Finn, George Sgouros et al. · Applied Radiation and Isotopes · 1999 · 138 citations

Engineering, Radiation Oncology, Clinical Engineering +7